Eli Lilly (NYSE:LLY) launched the Change the Course Commitment, an initiative aimed at increasing access to its diabetes and obesity medicines in resource-limited settings before 2040.
Eli Lilly (NYSE:LLY) received U.S. Food and Drug Administration approval on September 24, 2026, for Onswik, a once-weekly basal insulin treatment for adults with type 2 diabetes.
Eli Lilly (NYSE:LLY) has completed its acquisition of Centessa Pharmaceuticals, a clinical-stage company focused on orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders.
Eli Lilly and Company (NYSE:LLY) filed six lawsuits against U.S. businesses accused of selling black-market retatrutide products, while the company continues efforts to report illegal sales to regulators and law enforcement.
Eli Lilly (NYSE:LLY) executed a definitive agreement to acquire AtaiBeckley (NASDAQ:ATAI) for a $2.8 billion upfront equity valuation.
Eli Lilly (NYSE:LLY) announced that its board of directors has declared a cash dividend of $1.73 per share on outstanding common stock for the third quarter of 2026.
